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Abstract
Use of small interfering RNA (siRNA) is a promising approach for AML treatment as the siRNA molecule can be designed to
specifically target proteins that contribute to aberrant cell proliferation in this disease. However, a clinical-relevant means of
delivering siRNA molecules must be developed, as the cellular delivery of siRNA is problematic. Here, we report amphiphilic
carriers combining a cationic polymer (2 kDa polyethyleneimine, PEI2) with lipophilic moieties to facilitate intracellular
delivery of siRNA to AML cell lines. Complete binding of siRNA by the designed carriers was achieved at a polymer:siRNA
ratio of ,0.5 and led to siRNA/polymer complexes of ,100 nm size. While the native PEI2 did not display cytotoxicity on
AML cell lines THP-1, KG-1 and HL-60, lipid-modification on PEI2 slightly increased the cytotoxicity, which was consistent
with increased interaction of polymers with cell membranes. Cellular delivery of siRNA was dependent on the nature of lipid
substituent and the extent of lipid substitution, and varied among the three AML cell lines used. Linoleic acid-substituted
polymers performed best among the prepared polymers and gave a siRNA delivery equivalent to better performing
commercial reagents. Using THP-1 cells and a reporter (GFP) and an endogenous (CXCR4) target, effective silencing of the
chosen targets was achieved with 25 to 50 nM of siRNA concentrations, and without adversely affecting subsequent cell
growth. We conclude that lipid-substituted PEI2 can serve as an effective delivery of siRNA to leukemic cells and could be
employed in molecular therapy of leukemia.
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the RNA interference (RNAi) to silence the aberrant protein(s)
responsible for the disease [5,6].
There are two main approaches for RNAi, using either a
plasmid encoding for short hairpin RNA (shRNA) or delivering
small interfering RNA (siRNA) where the shRNA transcription
and processing steps can be omitted [7]. The use of siRNA is a
more practical approach bypassing the need to express the shRNA
at sufficient quantities in hard-to-transfect primary cells. In cytosol,
the siRNA duplexes assemble into a pre-RISC (RNA-induced
silencing complex) containing specific proteins, including argonaute proteins (AGO1, 3 or 4) [8,9]. The siRNA duplexes become
unwound in AGOs, where the guiding strand directs the matureRISC to target desired mRNA based on complementary base
pairing [8]. Endonucleoyltic cleavage and/or translational repression of the mRNA [8,9] subsequently silences the desired protein
target. Delivery systems, however, are an absolute necessity for
effective use of siRNA since the molecules are highly sensitive to
serum nucleases and their large (,13 kDa) and anionic nature
(due to its phosphodiesterase backbone) prevents siRNA to
traverse cellular membranes. Cationic biomolecules capable of
binding and neutralizing the anionic charges of siRNA and

Introduction
Acute myeloid leukemia (AML) is the most common acute
leukemia in adults, with an estimated .13,000 new cases yearly
and a mortality rate of ,10,000 in the US alone [1]. Development
of novel AML therapies is urgently needed due to poor prognosis
of the disease with a five-year survival rate of 30% for younger
adults and ,15% for elderly patients [2]. Only in childhood AML,
,60% of patients can be cured of AML with very intensive
chemotherapy [3]. The chemotherapy remains the front-line
treatment, but alternative therapeutic approaches are required due
to high relapse rates and limited treatment options for patients that
cannot bear the toxic side-effects of chemotherapy [4]. Chemotherapy also leads to long-term undesired consequences; ,66% of
survivors have either a chronic or late-effect due to cancer
treatment and ,33% of these effects are considered major, serious
or life threatening [1]. With better understanding of molecular
changes in malignant transformations, treatments that target
tumor-specific changes will lead to more effective therapies as the
normal cells transform into malignant cells. Towards this end, a
highly specific leukemia therapy can be developed by exploiting
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encouraging data to pursue the described carriers for siRNAbased molecular therapy of leukemia.

packaging the siRNA into nano-sized complexes can serve as
effective siRNA carriers [10]. The utility of cationic carries for
siRNA therapy in AML has been explored as early as 2003, where
Raf-1 and Bcl-2 proteins were suppressed in AML cells by using
the synthetic carrier OligofectamineTM. However, the resulting
apoptotic response required 400 nM siRNA [5], a concentration
too high for practical applications. It was evident that a more
efficient delivery system was required to advance siRNA therapy
for AML. Recent RNAi delivery attempts in leukemia cells have
employed a variety of commercial carriers, which included; (i)
LipofectamineTM 2000 in chronic myeloid leukemia (CML) K562
cells, and AML cells (KG-1/HL-60/U937/primary) [11–16], (ii)
RNAiMAXTM in K562 [17], (iii) HiPerFectTM in K562 and TALL (Jurkat) cells [18,19], (iv) DOTAP in Bcr-abl positive CML
cells (2Dp210-modified/patient samples) [20], (v) Lipofectin in
myeloid neoplasm cells (HMC-1) [21] (vi) and OligofectamineTM
in T-cell lympoblastic leukemia cells (CCRF-CEM) [21]. Other
carriers used for siRNA delivery were cell penetrating peptides
(Tat–LK15 peptide in K562 cells) [16], CADY peptide in THP-1
cells [23], and functionalized carbon nanotubes in K562 cells [24].
Many of the above studies focused on discovery of possible targets
for silencing and/or mechanisms of drug action, without pursuing
siRNA delivery as a therapy. A systematic analysis of carrier
features responsible for effective siRNA delivery was not conducted, which is critical for design of more effective siRNA carriers
suitable for clinical use.
We previously reported on siRNA delivery by amphiphilic
cationic polymers with lipid substituents to anchorage-dependent
malignant cells [25]. The polymers provided the necessary cationic
charge for siRNA binding whereas the lipid component provided
the hydrophobicity for improved interactions with cellular
membranes. The polymeric component was derived from
polyethylenimine (PEI), whose prototypical member, 25 kDa
branched PEI (PEI25), is widely used as an effective transfection
agent [26–28]. Since the cytotoxicity of PEI25 has been a major
impediment for its therapeutic use, we employed a smaller PEI
(2 kDa; PEI2) as the polymer backbone since it displays minimal
cytotoxicity [29–34]. Although PEI2 displays effective binding to
nucleic acids in buffers, the resultant complexes were ineffective
for nucleic acid delivery into cells. Lipid substitution on PEI2
enhanced the assembly of nucleic acids into nano-particles,
improved the cellular uptake and, depending on structural features
of lipid substituents, enabled silencing of selected molecular targets
in breast cancer cells [25,35]. Leukemic cells, on the other hand,
are structurally different from anchorage-dependent cells, with
minimal surface area and endocytic activity, and are known to be
difficult to transfect (as discussed in [36]).
This study explored the utility of lipid-substituted polymers for
siRNA delivery to leukemic cells. It was our aim to determine the
relative effectiveness of these carriers for siRNA delivery and to
elucidate carrier features critical for delivery. We focused on AML
subgroup of leukemia and employed 3 well-characterized cell
models (THP-1, KG-1 and HL-60 cells). The PEI25 was
employed as a reference reagent, given its prominent use for
siRNA delivery to anchorage-dependent cells. A systematic
approach was employed to investigating the role of lipid
substitution as well as the nature of substituted lipid on siRNA
binding, toxicity, and siRNA delivery and silencing. The results
showed that (i) PEI25 was not effective in siRNA delivery to
leukemic cells unlike the anchorage-dependent cells, and (ii) lipid
substitution improved the siRNA delivery of cationic polymers,
and (iii) effective silencing could be obtained at clinically
acceptable siRNA doses (20–50 nM). These results provide
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Materials and Methods
2.1 Materials
PEI25 (Mn: 10 kDa, Mw: 25 kDa) and PEI2 (Mn: 1.8 kDa, Mw:
2 kDa), anhydrous dimethyl sulfoxide (DMSO), myristoyl chloride
(C14; 97%), palmitoyl chloride (C16; 98%), octanoyl chloride
(C18:1 9Z; 99%), linoleoyl acid (C18:2 9Z, 12Z; 99%), 3-(4,5demethyl-2-thiazoylyl)-2,5-diphenyl-2H-tetrazolium
bromide
(MTT), N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethylammonium propane methylsulfate (DOTAP), trypan blue solution (0.4%), and
heparin sodium from porcine intestinal mucosa were purchased
from Sigma-Aldrich (St. Louis, MO). Stearoyl chloride (C18;
.98.5%) was obtained from FLUKA. Clear filtered HBSS
(phenol red free) was prepared in-house. Unlabeled negative
control siRNA, 59-carboxyfluorescein (FAM)-labelled negative
control siRNA, GFP siRNA (GFP-22) and CXCR4 siRNA
(HSC.RNAI.N001008540.12.1) were purchased from Ambion
(Austin, TX), Shanghai GenePharma Co., Ltd (Shanghai, China)
and Qiagen (Toronto, ON) and IDT (Coralville, IA), respectively.
Hanks Balanced Salt Solution (HBSS), Dulbecco’s modified Eagle
medium (DMEM; low glucose with L-glutamine; 11885), and
RPMI Medium 1640 with L-glutamine (11835), opti-MEMH I
reduced serum medium (31985), penicillin (10000 U/mL), and
streptomycin (10 mg/mL) were from Invitrogen (Grand Island,
NY). Fetal bovine serum (FBS; A15-751) was purchased from PAA
Laboratories Inc. (Etobicoke, ON). RNAi-mate was obtained from
Shanghai GenePharma Co., Ltd, LipofectamineTM 2000 and
LipofectamineTM RNAiMAX Reagent from Invitrogen, Metafectamine Pro from Biontex (San Diego, California) and FuGENEH
HD from Roche (Laval, QC) and HiPerFect Transfection Reagent
from Qiagen (Mississauga, Ontario).

2.2 Cell Models and Culture
The cell lines THP-1, KG-1 and HL-60 cells used as the AML
models were obtained from the American Type Culture Collection
(Manassas, VA). THP-1 and KG-1 cell were maintained in RPMI
medium and HL-60 cells were maintained in DMEM Low
Glucose medium, all containing 10% FBS (heat inactivated at
56uC for 30 min) and 1% penicillin/streptomycin under normal
conditions (37uC, 5% CO2 under humidified atmosphere). The
cells were maintained at concentrations between 0.16105 and
46105 cells/ml (monitored by hematocytometer cell counts) and
by weekly passage by dilution after removing the spent medium
with centrifugation at 600 rpm (72 g) for 5 min. To obtain Green
Fluorescent Protein expressing THP-1 cells, a retroviral vector
expressing enhanced GFP (EGFP) was generated by cloning EGFP
into pMSCVpuro (Invitrogen). The murine stem cell virus-based
vector was chosen as it provides relatively stable long-term
expression of the transgene and is less prone to transcriptional
shutdown in THP-1 cells than other retroviral vector systems
tested. To generate retroviral particles, pMSCV-EGFP was
transfected into 293T cells with Fugene HD. Gag/pol were
provided in trans and VSV-G was utilized as viral coat protein.
Retroviral supernatants were harvested 24 h post transfection and
used to transduce THP-1 cells. The cells were then selected using
puromycin and further enriched for EGFP expression using
fluorescence activated cell sorting. The resulting GFP-expressing
THP-1 cells were cultured as above.
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of cell viability was calculated as follows: 100% x (absorbance of
polymer treated cells/absorbance of untreated cells).

2.3 Synthesis of Lipid-Substituted Polymers
The PEI2 polymers substituted with lipids (caprylic acid; CA,
palmitic acid; PA, oleic acid; OA, linoleic acid; LA; stearic acid;
StA, myristic acid; MA) were prepared in house, where the
synthesis and characterization have been previously described
[37,38]. Briefly, a 2 kDa PEI solution (50% in water) was first
purified by freeze-drying. Commercially available lipid chlorides
(CA, PA, OA, LA, StA and MA) were then substituted by Nacylation of PEI onto the amine groups by addition of the lipid
chlorides to 100 mg of PEI in DMS0 for 24 h at ambient
temperature under argon. To produce a range of substitution
levels for each lipid, four different feed ratios were utilized
(lipid:polymer = 0.012, 0.066, 0.1 and 0.2) and the polymers were
precipitated and washed with excess ethyl ether. The lipidsubstituted polymers were dried under vacuum at ambient
temperature over night. The substitution was analysed by 1HNMR (Bruker 300 MHz; Billerica, MA) in D2O). The characteristic proton shifts of lipids (d,0.8 ppm; -CH3) and PEI (d,2.5–
2.8 ppm; NH-CH2-CH2-NH-) were integrated and normalised to
the number of protons in each peak in order to calculate the lipid
substitution levels. Table S1 summarizes the employed feed ratios
as well as the final level of lipid substitutions obtained. The
numbers of lipid methylenes substituted in each polymer were
calculated by multiplying the level of lipid substitution (from 1HNMR) with the number of methylenes in each lipid. Percent lipid
substitution was calculated by dividing the number of lipid
substituted with the number of amines available in each PEI2 (14).

2.6 Analysis of siRNA Binding to Polymers
Gel electrophoresis was performed for assessment of siRNA
binding efficiency of polymers, as well as for dissociation of
siRNA/polymer complexes with heparin. For the binding studies,
3 mL of 0.1 mg/mL control siRNA (in ddH2O) was incubated
with various concentrations of polymers (in ddH20) in 25 mL of
150 mM NaCl for 20 min to form complexes. Loading dye (4 mL,
6x, 40% sucrose with bromophenol blue/xylene cyanole) was
added to samples and the samples were run on a 0.8% agarose gel
containing 1 mg/mL ethidium bromide (130 V for 20 min). The
gels were visualized under UV illumination and bands corresponding to free siRNA were quantified by spot densitometer.
siRNA alone was run as a reference control (i.e., 0% binding).
Percent binding (%Binding) was calculated as: 100% 6 [(control
siRNA 2 free siRNA) 4 control siRNA]. Percent binding was
plotted as a function of polymer concentration and concentration
required for 50% binding of siRNA (BC50) was estimated based on
sigmoidal curve fits.

2.7 siRNA Delivery to Leukemia Cells
Effectiveness of carriers for siRNA delivery was determined by
measuring the percentage of cells positive for siRNA and mean
fluorescence of cells after delivery of FAM-labelled control
(scrambled) siRNA (CsiRNA-F). To account for cellular autofluorescence due to complex exposure, a non-labelled scrambled
(control) siRNA (CsiRNA) was utilized as a control for each
siRNA-polymer complex prepared. In cases where the results from
CsiRNA are not shown, the autofluorescence was found to be
insignificant. THP-1, KG-1 or HL-60 cells were seeded in 24-well
plates (0.35 mL fresh medium/well) and allowed to acclimatize for
24 h in normal maintenance conditions. The siRNA-polymer
complexes were prepared as in Section 2.4 and 10 ml of complex
solution was slowly added to each well containing the cells
(0.35 mL medium/well in triplicate). A 30 min of complex
formation between the siRNA and the polymers was found to
give the optimal uptake (Figure S1), so that complexes were
exposed to the cells after this incubation time. At indicated time
points (see figure legends), the cells were transferred to eppendorf
tubes and centrifuged (1200 rpm; 100 rcf). Cells were washed with
clear HBSS, resuspended in 100 ml of clear HBSS and then fixed
with 3.7% formalin in HBSS. The siRNA delivery to the cells was
assessed by flow cytometry (Cell Lab QuantaTM SC; Beckman
Couter) using the FL-1 detection channel, fluorescence plate
reader at lEX of 485 nm and lEM of 527 nm (Fluroskan Ascent,
Thermo Labsystems), or by epifluorescence microscopy (FSX100;
Olympus) as elaborated in the figures.
Competitive inhibition studies were performed by incubating
the cells with free lipids (LA, OA, StA; 0–100 mM) followed by
treatment of the cells with FAM-labelled siRNA/polymer complexes. Effect of serum on complex delivery was also determined;
the percentage of FBS in medium was varied between 0 and 50%
prior to complex treatment and cell uptake was determined by
flow cytometry as described above.
For internalization studies, siRNA delivery was performed as
described above with the following modifications. Delivery was
performed at both 4 and 37uC from 1 to 24 h and subsequently
split into trypan blue treated and non-treated groups. For the 4uC
groups, cells were placed at 4uC, 20 min prior to addition of
complexes and immediately put on ice in subsequent steps. At
each time point, cells were transferred to 1.5 ml tubes, centrifuged
and the medium was removed. Each group was split into a trypan

2.4 siRNA/Polymer Complex Formation
Polymer/siRNA complexes were formed by first adding a
desired amount of siRNA (0.37 mg; 25 nM final siRNA well
concentration) to 150 mM NaCl solution. The polymers (PEI25,
PEI2 and lipid-substituted PEI2s; all dissolved in ddH2O) were
then added to the siRNA solutions at desired polymer:siRNA
ratios (8:1, 4:1 and 2:1 w/w, corresponding to 63.2:1, 31.6:1,
15.8:1 N/P ratios), bringing the volume to 30 mL. After mixing,
the complexes were incubated at room temperature for 30 min
before addition (triplicate; 10 mL/well) to the cells (note that 30
minutes of complex incubation was within the optimal range for
siRNA delivery; Figure S1). For electron microscopy imaging,
complexes were prepared in the same manner, except the
150 mM NaCl solution was replaced with ultra pure water to
prevent NaCl crystal formation. After 30 min of incubation, 5 mL
of complex solution was transferred to a 3 mm Formvar film
coated grid. The grid was allowed to dry (,20 min) and
complexes were imaged by a Philips/FEI (Morgagni) Transmission Electron Microscope with CCD camera (TEM-CCD).

2.5 Cytotoxicity
The extent of the polymer/siRNA complex cytotoxicity was
determined by the MTT assay. The complexes were prepared at
8:1 w/w ratio as described above. The cells were seeded in 24-well
plates with 0.5 mL medium per well and allowed to acclimatize for
24 h. The complexes were then added in triplicate for final
concentrations of 1.25, 2.5, 5 and 10 mg/mL and incubated for
24 h under normal maintenance conditions. The MTT solution
(40 mL, 4 mg/mL in HBSS) was then added to each well and the
cells were incubated for 2 h. The plates were centrifuged, the
medium removed, and 200 mL of DMSO was added to each well
to dissolve the MTT crystals formed. The optical density of the
solutions (570 nm) was measured by an ELx800 Universal
Microplate Reader (BioTek Instruments; Winooski, VT, USA).
Background was determined with medium only wells and
subtracted from the obtained optical densities. The percentage
PLOS ONE | www.plosone.org
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blue and a without trypan blue group. 100 ml of 0.4% trypan blue
in HBSS (or HBSS) was added to each tube (containing 100 ml
medium) and cells were resuspended and incubated for 5 min.
They were then fixed with 3.7% formalin and washed twice with
1 ml HBSS (to remove trypan blue) prior to flow cytometry.
A comparison between lipid-substituted polymers and commercial reagents (RNA-mate, LipofectamineTM 2000, RNAiMAXTM,
Metafectamine, DOTAP, Fugene HD and HiPerFect) was
performed by delivering siRNA complexes (24 h) prepared with
CsiRNA-F. Complexes were prepared as closely as possible to the
manufactures directions while maintaining a consistency necessary
for comparison. The incubation time with the cells, medium
volume and type and serum concentrations were all standardized.
As most vendors suggest the use of OPTI-MEM for complex
preparation, the complexes were prepared with OPTI-MEM as
the buffer. siRNA (0.37 mg) and desired reagents was added to
150 mL OPTI-MEM solutions separately. The reagent amounts
were 2.9 mL (1 mg/ml) for PEI25 and PEI2-LA20, 5.9 mL for
RNAi-mate, 4 mL for LipofectamineTM 2000, 7.5 mL for RNAiMAXTM (pre-diluted 1:4 in OPTI-MEM), 1.8 mL for Metafactamine, 4 mL for Fugene HD, 2.2 ml for DOTAP (1 mg/mL), and
4.5 mL for HiPerFect (pre-diluted 1:4 in OPTI-MEM). The
amount of the reagents was halved for low concentration
experiment. The siRNA and reagent solutions were then vortexed,
except Metafectamine that was mixed by pipetting once. The
siRNA-reagent solutions was then mixed by gently vortexing
except for DOTAP which was mixed by pipetting and
Metafectamine which was not mixed. PEI25, PEI2-LA20 and
RNAi-mate complexes were incubated for 30 min, LipofectamineTM 2000, RNAiMAXTM and Metafectamine were incubated for
20 minutes, Fugene HD and DOTAP were incubated for 15 min
and HiPerFect was incubated for 10 min, prior to drop-wise
addition (100 mL) to cells in 200 mL of RPMI medium. The
commercial reagents were ranked (from 1 to 9; 1 being the best
and 9 being the worst) according to siRNA uptake results from
flow cytometry, based on percentage of cell population positive for
siRNA and mean siRNA fluorescence/cell. If reagents had
comparable fluorescence levels (due to overlapping SDs), their
ranks were averaged and each was given the same mean value.
The ranking was then averaged over the three cell lines to provide
an overall performance ranking.

cells was calculated as follows: [% of GFP-negative cells of
GFPsiRNA/polymer treated cells] - [% of GFP-negative cells of
CsiRNA/polymer treated cells]. Gating was performed as
described in Section 3.7.
For studies where GFP silencing was followed at the mRNA
level, total RNA was extracted from treated THP-1 cells in 12-well
plates (biological duplicates) with the RNAeasy Mini Kit (Qiagen).
The extracted RNA was then quantified by spectrophotometry
(GE Nanovue). cDNA was synthesised following Invitrogen’s
protocol, briefly adding 2 mL master mix 1 (0.5 mL Oligo(dT)12–18
Primer, 0.5 mL random primers and 1 mL (10 mM) MdNTP’s per
sample) to 10 mL of RNA (2500 ng) and then heated at 65uC for
5 min. 7 mL of Master Mix 2 (4 mL 5 6 Synthesis Buffer, 2 mL
DTT (0.1 M) and 1 mL RNAout RNase inhibitor (1.8 U/mL)) was
then added and the samples heated at 37uC for 2 min. 1 mL of MMLV RT enzyme was then added per sample and they were
heated at 25uC for 10 min, 37uC for 50 min and 70uC for 15 min.
Real-time PCR was performed on a ABI 7500 HT with human
beta actin (Forward: 59-CCA CCC CAC TTC TCT CTA AGG
A-39 Reverse: 59-AAT TTA CAC GAA AGC AAT GCT ATC A39) as the endogenous house keeping gene and the specific GFP
primers (Forward: 59-GGG CAC AAG CTG GAG TAC AAC-39,
Reverse: 59-CAC CTT GAT GCC GTT CTT CTG -39). 7.5 mL
of master mix containing 5 mL of 2X SYBR Green master mix
(MAF Centre, U. of Alberta) and 2.5 mL primer (3.2 mM; per
sample) was added to each well. Then, 2.5 mL of template of each
sample was added in triplicate. A template concentration
(9.76 ng/uL) was determined optimal based on a standard curve.
To ensure that the efficiencies of the human beta actin and GFP
primers were approximately equal, to validate use of the 22DDCT
method, DCT vs. cDNA dilution was plotted and the slope was
verified to be approximately zero. Analysis was performed by
22DDCT method [39] using the no-treatment group as the
calibrator. Finally, the change in mRNA levels (in percent form)
was calculated as follows: [% mRNA rel. NT of cells treated with
CsiRNA/polymer complexes] – [% mRNA rel. NT of cells treated
with GFPsiRNA/polymer complexes]. Standard deviation was
calculated from the biological replicates.

2.9 CXCR4 Silencing in THP-1 Cells
THP-1 cells were treated with CXCR4 siRNA or control
siRNA by using the polymer complexes (4:1) as described above.
At day 2 and day 3, cells were stained with 4 mL of PE-labeled
mouse anti-human CXCR4 (CD184) or PE-labeled mouse IgG
isotype control (BD Pharmingen) antibody in 90 mL of medium
(after centrifugation and resuspension) for 45 min at room
temperature. They were subsequently re-suspended in HBSS
and fixed in 3.7% formalin and immediately analysed by flow
cytometry (FL2 channel). As in GFP analysis, changes in mean
CXCR4 levels (based on Ab fluorescence levels) and the CXCR4positive cell population were calculated. The cell population
stained with non-specific antibody was used for flow cytometry
calibration (i.e., 1% CXCR4-positive population).

2.8 GFP Silencing in THP-1 Cells
GFP-expressing THP-1 cells were used as a model for silencing
studies. siRNA complex formation and delivery to the cells was
performed as described in Section 2.4 and 2.7, utilizing GFP
specific siRNA (GFP-siRNA) and scrambled siRNA (CsiRNA).
For the time course studies, cells were treated with desired siRNAs
continuously during the experimental duration; cells were
subcultured every 3 days to prevent over-growth. Subculturing
was performed by dilution (x10) into fresh medium after
resuspension. All groups were subcultured with the same ratio
regardless of cell concentration to ensure that the concentration of
any remaining complexes stayed constant. For studies including
the commercial reagents, selected reagent preparation was
performed with OPTI-MEM as described in Section 2.7 for the
commercial reagent delivery comparison study, keeping the same
reagent:siRNA ratios (high ratios) and at siRNA concentration of
50 nM. GFP silencing was assessed by flow cytometry after cell
fixation (as described in Section 2.7) using the FL-1 detection
channel. Percent decrease in mean fluorescence was calculated as
follows: 100 - {[Mean FL1 of cells treated with GFP-siRNA/
polymer complexes ]/[Mean FL1 of cells treated with CsiRNA/
polymer complexes] x 100%}. Percent decrease in GFP-positive
PLOS ONE | www.plosone.org

2.10 Statistical Analysis
Results are displayed as the mean 6 standard deviation (SD) of
triplicate samples. For binding and dissociation studies, variations
between the group means were analyzed as described in figures.
To determine linearity, linear regression was performed; r2
coefficient and P values (to test for significant slope) were reported.
Statistical analysis was performed with GraphPad InStat v3.06
(GraphPad Software, San Diego, CA USA).
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Figure 1. Binding of lipid-substituted polymers to siRNA. Percentage of siRNA bound as a function of polymer:siRNA weight ratio in EMSA
analysis. Polymers obtained from lipid:polymer feed ratios of 0.012, 0.066, 0.1 and 0.2 are shown in A, B, C and D, respectively.
doi:10.1371/journal.pone.0044197.g001

of a fluorescent probe to free sites on siRNA. As expected,
increasing the polymer:siRNA ratio during complex formation
resulted in an increase in siRNA binding for all polymers
(Figure 1). The binding curves typically followed a sigmoidal
curve for most polymers, except a few linear curves obtained for
some polymers (e.g., PEI2-LA20 in Figure 1D). The linear curves
were usually the case for polymers with lower capacity for siRNA
binding. The PEI25 and PEI2 typically yielded the most binding at
a given polymer:siRNA ratio as compared to lipid substituted
equivalents, indicating a lowering of binding efficiency after lipid
substitutions. Based on the generated curve fits, BC50 values were
determined as a relative measure of the siRNA binding efficiency.
The PEI2 and PEI25 had the lowest BC50 values among the
polymers (0.07 and 0.09, respectively), and all lipid-substituted
polymers displayed a BC50 value higher than the native PEIs
(Figure 2). For some lipids (PA and OA), a general trend of
increasing BC50 with increasing lipid substitution was clearly
evident, but not all lipids (CA and StA) gave such a clear trend. A
more general relationship between the degree of lipid substitution
and BC50 values was explored based on the correlation coefficient
between BC50 and the extent of lipid substitution for all polymers.
The obtained linear regression coefficient (r2,0.2024; dashed line
in Figure 2A) indicated a relatively weak but a significant
correlation (p,0.05) between the two variables. Since each type of
lipid contained a differing number of lipid carbons, we also

Results and Discussion
Lipid substitution to PEI2 was explored as a means to improve
siRNA delivery to AML cells, THP-1, KG-1 and HL-60. The
substituted lipids included CA, MA, PA, StA, OA and LA (in the
order of increasing carbon chain length form C8 to C18) at a
range of substitution levels (Table S1) [37,38]. There was a
general increase in lipid substitution as the lipid:PEI feed ratio was
increased during the synthesis (determined by 1H-NMR). The
highest number of lipids substituted was achieved with CA at
lipid:PEI amine ratio of 0.2 (6.9 CAs/PEI). All polymers remained
water soluble, except PEI2-StA20 that had the highest number of
lipid methylenes substituted per PEI2 chain (89.0) and it was
excluded from the study.

3.1 Polymer Binding to siRNA
It is imperative for the polymers to bind and neutralize the
anionic charge of siRNA to form a siRNA complex. The siRNA
binding ability polymers was determined by the semi-quantitative
EMSA using CsiRNA. The fraction of unbounded siRNA (i.e.,
free siRNA capable of moving into the gel) was determined in this
assay, which was used to calculate the amount of siRNA
participating in complex formation. This method is similar to
quantitative dye binding assay based on SYBR Green [25], but
actually measures complex formation directly rather than binding
PLOS ONE | www.plosone.org
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complexes [41], consistent with larger size of plasmid DNAs used
to assemble the particles.
In order to minimize the scale of further experiments, the lowest
substitution for each polymer was excluded from the experiments
as they are expected to be the least different from the unmodified
PEI2. Additionally, MA- and StA-substituted polymers were
excluded, as these substitutes did not appear to be unique in the
extent of substitutions and the siRNA binding studies.

3.2 Cytotoxicity of Polymeric Carriers
It is well established that the high MW PEI25 generally displays
high cytotoxicity in contact with cells, whereas low MW PEIs
display minimal cytotoxic effects [29–34]. High MW polymers
were suggested to be more effective in creating membrane
invigilations and/or pores, which is desirable for siRNA delivery,
but this also causes more harm on the cells by disrupting
membrane integrity [42]. While lipid-substitution is intended to
increase membrane affinity of polymers, our lipid-modified
polymers are expected to expose the cells to lipid concentrations
of 1–10 mM, assuming a polymer concentration of ,6 mg/mL in
contact with the cells (practical concentration used for siRNA
delivery) and average lipid substitutions of ,3 lipids/PEI2. The
lipids are naturally occurring molecules and palmitic, oleic and
lineloic acids are present in plasma membranes. Additionally, the
toxicity of lipids on leukemia cell lines have been investigated;
tolerable concentration of lipids in Jurkat (human T leukemic) and
Raji (human B leukemic) cell lines depended on the specific lipids,
but all concerned lipids were tolerable at ,50 mM [43], a value
much higher than lipid concentrations to be exposed to cells with
our carriers.
The cytotoxicity of the complexes on AML cells is summarized
in Figure 4. As expected, PEI25 displayed an obvious,
concentration-dependent toxicity in all cells. The PEI2 displayed
minimal toxicity that was evident only in HL-60 cells (see Table
S2 for detailed analysis of cytotoxicity trends). For lipid-substituted
PEI2, a concentration dependent loss of viability was evident for
some cell-polymer pairs, but other polymers did not display
toxicity in the investigated concentration range. However,
cytotoxicity of the PEI2 and PEI2-lipids did vary among the cell
lines. For THP-1 cells, minimal toxicity was observed with CA and
PA substitutions, while OA and LA substituted PEI2 gave a
significant decrease in cell viability. In KG-1 cells, minimal, if any,
decrease in cell viability was seen with CA, PA and OA
substitutions, while a slight increase in cytotoxicity was seen with
LA substituted PEI2. For HL-60 cells, PEI2 substitutions with CA
and PA displayed no changes in cytotoxicity, but OA and LA
substitutions displayed a small negative effect on cell viability.
Taken together, LA was the only lipid substituent that clearly
increased the cytotoxicity of the polymers in all three cell lines.
This was presumably due to better interaction of this type of
polymer with these AML cells.
Since a major concern of polymeric carriers is the dosedependent cytotoxicity [44], as obviously manifested with the
PEI25, it is notable that our carriers did not display definitive doseresponse curves in investigated cell lines. Relatively low cytotoxicity is the likely reason for the lack of clear dose-response curve.
We previously noted that lipid substitution generally increased the
toxicity of PEI2 on anchorage dependent bone marrow stromal
cells [38] and breast cancer cell line MDA-435 [25]. To further
explore this issue with leukemic cells, a correlation between the
lipid substitution and the resulting cytotoxicity was explored as in
the binding studies (Table S3). Very few obvious correlations
occurred in this analysis; the strongest trends were seen at the
highest polymer concentrations of 10 mg/ml where high r2 and

Figure 2. Correlations between polymer binding affinity IC50
and extent of lipid substitutions. IC50 is shown as a function of
number of lipids substituted (A) or number of lipid methylenes
substituted (B). As lipid substitution is increased, the binding affinity
(given by IC50) decreased. Statistical analysis was determined by
Student’s t-test (p,0.05).
doi:10.1371/journal.pone.0044197.g002

explored a correlation between the BC50 and the extent of lipid Cs
substituted (see Table S1 for exact values of lipid Cs). The
regression coefficient obtained was relatively higher (r2,0.2828;
dashed line in Figure 2B), again indicating a significant
correlation (p,0.01) between these two variables.
TEM imaging for the complexes with native PEIs (PEI25 and
PEI2) and representative CA, PA, OA and LA substituted PEI2
are summarized in Figure 3. Distinct complexes were observed in
most cases, but some polymers (PEI2 and PEI2-PA) gave
aggregated particles where smaller spherical particles appeared
to fuse together. Fusing of particles in TEM images have been seen
in other studies as well [40], which was likely due to drying during
the sample preparation. Most complexes appeared relatively
homogenous (similar contrast throughout the complex) with the
exception of PEI2-OA, where spherical particles appeared to be
multiphasic. The size of individual complexes were typically
,100 nm, with PEI2-OA particles being notably larger
(.200 nm). Directly comparable images of TEM complexes, such
as PEI25/siRNA or PEI2/siRNA complexes, are not available in
the literature; however, TEM imaging of PEI25/plasmid DNA
complexes were reported to be larger than our PEI25/siRNA
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Figure 3. Morphology of polymer/siRNA complexes imaged by TEM. (A) PEI25 complexes, (B) PEI2 complexes, (C) PEI2-CA20 complexes, (D)
PEI2-PA20 complexes, (E) PEI2-OA20 complexes, (F) PEI2-LA20 complexes. All complexes were prepared at an 8:1 polymer:siRNA weight ratio. Scale
bar in the high magnification images indicates 200 nm.
doi:10.1371/journal.pone.0044197.g003

fluorescence in cells are summarized in Figure 5A. Exposure of
the cells to CsiRNA did not indicate significant autofluorescence at
the low concentration, but a significant autofluorescence was
evident at the high polymer concentration (8 mg/mL) with PEI2PA. The PEI2-PA was successful in delivering siRNA to majority
of the cells (.50%) at both doses and also demonstrated higher
delivery than PEI25, which gave a lower percentage of siRNApositive cells (,16%) that decreased at higher complex dose. This
decrease was likely due to high toxicity of PEI25 at the 8 mg/mL
used in this experiment. The low effectiveness of PEI25 was unlike
most siRNA delivery studies reported in the literature that
typically employed anchorage-dependent cells, such as human
breast cancer cells [25,35,46], mouse albino neuroblastoma cells
[27], human ovary cells [28], human prostate carcinoma cells
[46], human cervical cancer cells [26], and mouse glioblastoma

significant slopes (p values) were observed for CA- and PAsubstitutions in KG-1 cell lines. Again, relatively low cytotoxicity
in the working range did not allow for a strong correlation and
toxicity at higher concentrations was not explored since this is not
the practical range for siRNA delivery.

3.3 siRNA Delivery with PA-substituted PEI2 to THP-1
Cells
Initial siRNA delivery studies were performed with THP-1 cells
and by using PEI2-PA as a prototypical carrier. Two concentrations of siRNA complexes (corresponding to 36 and 72 nM siRNA
and, 4 and 8 mg/mL polymer) were used in this study, as well as an
unlabeled siRNA (CsiRNA) as a control to account for the
possibility of autofluorescence displayed with certain carriers [45].
The percentage of cells with siRNA uptake and the mean siRNA
PLOS ONE | www.plosone.org
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Figure 4. Cytotoxicity of complexes on THP-1, KG-1 and HL-60 cells (top, middle and bottom panel, respectively). Cell viability values
are expressed relative to no-treatment control. Viability was measured 24 h after incubation of complexes with cell lines. PEI25 displays a linear
relationship with increased cytotoxicity in line with increasing concentration. Effect of lipid-substituted polymers on cell viability was similar to that of
unmodified PEI2. * : p,0.05, ** : p,0.01, as compared to PEI2 and o : p,0.05, oo : p,0.01 as compared to PEI25, using one-way ANOVA tests with
Dunnett post test.
doi:10.1371/journal.pone.0044197.g004

but not with PEI25 and PEI2 (Figure 5D). It was therefore clear
that the lipid substitution on PEI2 (PA in this case) mediated
improved delivery of siRNA to the leukemic cells.

cells [47]. The ineffectiveness of PEI25 in haematopoietic cell lines
was previously noted for delivery of plasmid DNA [48], which
found PEI2 to be superior to PEI25. Unlike the study on the
plasmid DNA delivery, the PEI2 was not effective in our hands for
siRNA delivery.
To further compare the relative efficiency of PEI25, PEI2 and
PEI2-PA, siRNA delivery was explored as a function of
polymer:siRNA ratio (Figure 5B) and seeded cell density
(Figure 5C). As before, PEI2 was not effective under all
investigated conditions. While PEI25 was more effective at lower
ratio (4:1), PEI2-PA was more effective at higher ratios (8:1 and
12:1), indicating the polymer:siRNA ratio to be critical for uptake.
As the cell concentration was increased, the percentage of siRNAassociated cells remained the same, but the mean fluorescence/cell
was decreased (Figure 5C), indicating less siRNA uptake/cell at
higher cell concentrations. Finally, confocal microscopic analysis
of the siRNA uptake confirmed the quantitative results obtained.
Distinct cell-associated complexes were clearly seen with PEI2-PA,

PLOS ONE | www.plosone.org

3.4 Effect of Lipid Substitution on siRNA Delivery
To develop a broader understanding of the role lipid
substitution on siRNA delivery, PEI2 substituted with CA, PA,
OA and LA were used to evaluate siRNA delivery to THP-1 cells
(Figure 6). The siRNA delivery varied significantly among the
polymers, whether it was assessed by the siRNA-positive cell
population (Figure 6Ai) or the mean siRNA level per cell
(Figure 6Aii). Based on these two parameters, siRNA delivery
was correlated to the number of lipids substituted/PEI2
(Figure 6Bi and 6Ci), the number of lipid methylenes/PEI2
(Figure 6Bii and 6Cii) and percentage of lipid substitution
(Figure 6Biii and 6Ciii). As shown in the table in Figure 6,
strong correlations (see r2 values listed in the figures) were observed
with PA and LA substitution in all cases. These positive
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Figure 5. siRNA delivery to THP-1 cells. (A) varying complex dose (0.5 and 1.0 mg/mL siRNA). (B) varying polymer:siRNA weight ratio. (C) varying
initial cell number (0.35 mg/mL siRNA). The results are summarized as (i) percentage of siRNA-associated cells in cell population, and (ii) mean
fluorescence of cells due to complex association. (D) confocal microscope images of individual cells (0.5 mg/mL siRNA). Hoechst stained nucleus in
blue and FAM-labelled siRNA-polymer complexes in green. Polymer:siRNA ratios were 2:1, 4:1 and 8:1 from top to bottom panel.
doi:10.1371/journal.pone.0044197.g005

,7% for 4uC incubated cells during the 24-hour study period
(Figure 7Bii). We note that the fluorescence levels obtained by
trypan blue treatment was greatly diminished (Figure 7Bi),
consistent with results reported by an independent group [49]. As
trypan blue coats the surface of the cells, it is likely that it
decreased the excitation of the internalized fluorescent complexes
within the cells.
Although the beneficial effect of lipid modification of carriers in
cellular delivery of nucleic acids is established [50], the mechanism(s) by which they due so remains ill-defined. It has been
suggested that the lipid modifications may elicit specific biological
responses in interacting with cellular membrane, facilitating
uptake and intracellular transport [50]. From a physical perspective, membrane phospholipids, consisting of various combinations
of lipids, significantly contribute to the membrane stability,
permeability and fluidity. Saturated lipids such as CA (C8) and
PA (C16) are linear and allow tighter membrane packing leading
to decreased fluidity and permeability, whereas unsaturated lipids
(one double bond in OA (C18:1) and two double bonds in LA
(C18:2)) introduces non-linear chains and disorder (and fluidity)
into membranes [51]. Therefore, it is not surprising that the LAsubstituted complexes will increase the membrane fluidity the most
and display the highest uptake. The composition of lipids in the
cellular membrane is another possible cause of variations in
delivery. In an analysis of lipid composition in AML cells, the
weight percentage of PA, OA and LA were 20.861.2%,
15.962.2% and 7.061.0% respectively (values equivalent to
healthy controls [52]). Similar percentages were also reported in
Jurkat (T-lymphocyte), Raji (B-lymphocyte) K562 cells, and foetal

correlations were indicative of lipid substitutions to be directly
responsible for intracellular siRNA delivery. Among the polymers,
PEI2-LA polymers appeared to be most effective, based on the
strong correlations between siRNA delivery and LA substitutions,
as well as absolute levels of siRNA delivery per cell. It was also
clear that the enhanced delivery was dependent on the individual
lipid, as the explored correlations failed if all lipid-substituted
polymers were considered together. This was unlike the case with
the binding studies where the correlation was valid with all lipids,
indicating a similar role of lipids on the siRNA binding, but
significantly different roles in delivering the siRNA to the cells.
To determine the extent at which the complexes are internalized as opposed to remaining surface-bound, a time course of
complex uptake was performed (Figure 7). The polymer that
provided the highest siRNA delivery, PEI2LA, was used for this
purpose in THP-1 cells. Trypan blue staining was employed to
differentiate between surface bound and internalized complexes,
since it quenches the fluorescence of surface-bound complexes
[49], as well as incubation at 4uC since it prevents active complex
internalization. A gradual increase in cell-associated siRNA was
evident in the first 24 hours for the cells incubated at 37uC
(Figure 7A), where ,80% of the cells became siRNA-positive
(Figure 7Aii). For cells incubated at 4uC, no further increase in
cell-associated siRNA was evident after the initial binding at 1
hour (Figure 7A). With trypan blue quenching, a continuous
increase in siRNA uptake was evident at 37uC, but not at 4uC
(Figure 7B). This was consistent with abolished active uptake at
the latter temperature. Whereas the proportion of siRNA-positive
cells gradually increased to ,42% at 37uC, this value remained
PLOS ONE | www.plosone.org
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Figure 6. Effect of lipid substitution on siRNA delivery to THP-1 cells. Polymer:siRNA ratio was 8:1 and siRNA concentration was 25 nM
(0.35 mg/mL). (A) siRNA delivery percentage (percentage of cells with complexes, i) and mean fluorescence (mean fluorescence of cells due to
fluorescence labelled siRNA-polymer complexes, ii). (B) Correlations between siRNA delivery percentage and lipid substitution. (C) Correlations
between mean fluorescence and lipid substitution. Very strong positive correlations (r2 values) are seen with PA and LA regardless how the lipid
substitution is expressed (no of lipid per PEI2, no of lipid methyl carbons per PEI2 or percentage of PEI2 amines substituted) and with both siRNA
delivery and mean fluorescence. Strong correlation (r2 value) is seen with CA when considering mean fluorescence. * indicates where the slope is
statistically significant.
doi:10.1371/journal.pone.0044197.g006

results suggested that free lipids did not affect the uptake of the
complexes, so that specific uptake was likely not the reason for
increased uptake of LA-containing complexes.

calf serum [43,53]. LA content seems to be significantly less than
the PA and OA contents. After incubation in LA-supplemented
medium, the LA content of cellular membranes can be increased
extensively (,20 times) [53]. It is conceivable that lipids that are
present at lower concentrations originally (i.e., LA) would be taken
up and incorporated in the cellular membrane to a greater degree.
Thus, in order to investigate the effect of specific lipid uptake into
the cellular membrane, cells were incubated with the free LA (0–
100 mM) for 24 h hours followed by siRNA uptake for 24 h. The
exposure of cells to LA prior to adding the complexes did not effect
siRNA delivery percentages, regardless of using polymer/siRNA
complexes at 2:1 or 8:1 polymer:siRNA (Figure S2A). Additionally, incubation of LA, OA and StA (0–50 mM) with simultaneous
siRNA complex (PEI2-LA, PEI2 and PEI25) treatment did not
influence the extent of siRNA delivery (Figure S2B). These

PLOS ONE | www.plosone.org

3.5 siRNA Delivery to Other AML cells
Two other AML cell lines, the acute myelogenouse leukemia
(M1) KG-1 cells and the acute promyelocytic leukemia (M2)
HL-60 cells, were next tested for siRNA delivery with the
modified PEI2s, along with the THP-1 cells (Figure 8). Of the
cell lines studied, KG-1 (M1) is the least differentiated
(myeloblast), HL-60 (M2) is in the early stages of differentiation
(promyeloblast) and THP-1 (M5) is the most differentiated
(monocyte). As classification is dependent on differentiation
stage, the cells vary in expression of the differentiation markers
CD11b and CD14 (monocytic markers) and CD33, CD13,

10

August 2012 | Volume 7 | Issue 8 | e44197

Non-Viral siRNA Delivery to Leukemic Cells

Figure 7. Effect of temperature (4 and 37uC) and trypan blue treatment on siRNA delivery to THP-1 cells. PEI2-LA (2.1 LA/PEI2) was used
in this study with polymer:siRNA ratio of 8:1 and final siRNA concentration of 25 nM (0.35 mg/mL). (A) siRNA delivery based on mean FAM
fluorescence (i) and FAM-siRNA positive cell population (ii) with untreated cells (B) siRNA delivery based on mean FAM fluorescence (i) and FAMsiRNA positive cell population (ii) with cells treated with trypan blue.
doi:10.1371/journal.pone.0044197.g007

cells. The decline was most likely a result of rapid cell proliferation,
as the doubling-rate of THP-1 cells is ,26 h and KG-1 and HL60 cells being slightly longer. In such a case, a rapid drop in the
levels of siRNA concentrations is expected, whereas the percentage of siRNA-positive cells might not change drastically. The latter
will be seen for cells where the siRNA amounts were lower (i.e., at
the detection threshold). As the variation of mean fluorescence
(given by standard deviations in Figure 9) did not increase with
time, it is reasonable to assume that the splitting of complexes
between the dividing cells were fairly even with internalized
siRNA not particularly restricted to mother or daughter cells. Even
with the prolonged time of analysis, both PEI25 and PEI2 did not
yield a significant siRNA delivery, based on the mean siRNA
fluorescence associated with the cell population (Figure 9ii).
Collectively, these results indicated that the uptake of the siRNA
complexes was relatively rapid (,6 h) and prolonged incubation
with complexes did not yield a ‘net’ accumulation of siRNA inside
cells.
As the interaction with serum proteins can affect delivery of
siRNA complexes, we explored the effect of serum on siRNA
delivery, utilizing the best performing polymer PEI2-LA
(Figure 10). At low serum percentage of 2.5%, PEI25
displayed comparable delivery percentage to PEI2-LA, although
the siRNA delivery/cell remained low as usual for this polymer.
However, as the serum concentration was increased, the
delivery ability of PEI25 decreased to a greater degree than
the PEI2-LA in all cell lines. In THP-1 cells, the effect of serum
on PEI2-LA delivery was evident even at low concentration (i.e.,
from 2.5 to 10%), whereas delivery was largely unaffected up to
25% serum in the KG-1 and HL-60 cells. Although, the
polymer-serum interactions were expected to produce similar
results in all cell lines as the serum percentage and polymer

CD65s, CD15/15s (myeloid markers), as summarized in [54].
The siRNA delivery was investigated at polymer:siRNA ratios of
2:1, 4:1 and 8:1. Various lipid substitutions were successful for
siRNA delivery to THP-1 cells, given by the large increases in
siRNA delivery after lipid substitution on PEI2 (Figure 8A). In
the KG-1 and HL-60 cells, LA-substituted PEI2 was again the
most effective (Figure 8B and 8C). Of the three different
polymer:siRNA ratios tested, the 8:1 ratio consistently gave the
best delivery. This was attributed to higher cationic charge of
the complexes formed at higher polymer:siRNA ratios [24],
which should facilitate better binding to anionic cell surfaces.
The PEI25 and PEI2 did not appear to be an effective delivery
agent for the KG-1 and HL-60 cells either, confirming our
previous observation with THP-1 cells. It was also evident that
the cells displayed differing propensity to uptake polymer/
siRNA complexes; whereas THP-1 appeared to be most readily
display siRNA uptake, KG-1 cells displayed the least uptake.
This was expected since KG-1 being the least differentiated
phenotype (leukemic progenitor cell) with minimal endocytic
activity and smaller size (12–16 mm) and THP-1 being the most
differentiated with larger size (15–20 mm) [55]. It will be
important to further explore the molecular basis of this
observation, since it might be an indicative of patient-to-patient
variations in siRNA delivery.
Time-dependent siRNA delivery was then assessed by utilising
only the polymers with the highest substitution levels at the best
performing ratio (8:1) and exposing the complexes to cells for a
period of up to 48 hours (Figure 9). The highest siRNA delivery
was obtained at the earliest time point (6 h). As time increased, the
percentage of cells associated with complexes and the mean
fluorescence/cell was decreased. The mean fluorescence levels
declined at a faster rate than the percentage of siRNA-positive
PLOS ONE | www.plosone.org
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Figure 8. siRNA delivery to THP-1, KG-1 and HL-60 cells at various polymer:siRNA weight ratios. (A) THP-1 (B) KG-1, and (C) HL-60 cells.
Fluorescence intensity refers to the mean fluorescence of the cell population. Non-labeled control siRNAs did not show any significant fluorescence
(autofluorescence) and were removed for figure clarity. siRNA concentration was 25 nM (0.35 mg/mL) and polymer:siRNA weight ratios were 2:1 (top
panel), 4:1 (middle panel) and 8:1 (bottom panel).
doi:10.1371/journal.pone.0044197.g008

remain the same, properties that promote of uptake, can be
dependent on the cell type. The ability to deliver siRNA in
serum is clearly important especially for leukemia cells, however
similar uptake studies in the presence of serum have not been
reported in literature for leukemic cells. Clearly PEI25 was
affected by the serum proteins to a much greater extent than
the lipid-modified PEI2. We previously found that lipid
PLOS ONE | www.plosone.org

substituted PEIs afforded better protection against degradation
in the presence of serum [40]. This observation along with the
uptake results suggest that the lipid modification decreased
interaction of complexed nucleic acids with serum proteins, so
that their delivery ability is less affected by high serum
concentrations.
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Figure 9. siRNA delivery to THP-1, KG-1 and HL-60 cells at various time points. (A) THP-1 (B) KG-1, and (C) HL-60 cells. Non-labeled control
siRNAs did not show any significant fluorescence (autofluorescence) and were removed for figure clarity. siRNA concentration was 25 nM (35 mg/mL)
and polymer:siRNA weight ratio was 8:1. The results are summarized as percentage of siRNA positive cells (top panel), mean fluorescence per cell
(middle panel).
doi:10.1371/journal.pone.0044197.g009

and the percentage of siRNA-positive cell population
(Figure 11C, bottom). The ranking was not consistent with
the two parameters assessed, indicating that the individual carriers
behaved differently in the extent of modification and the mean
siRNA delivered into each cell type. We noted a significant
variation in siRNA delivery among the three cell types for these
different carriers, as noted in Figure 9 as well.
There has not been any comparison of the efficiency of
commercial reagents for siRNA delivery to leukemic cells, but it is
clear that large differences in efficiency existed among these
reagents. LipofectamineTM 2000, Metafectamine and Fugene HD
seemed to be sufficiently effective when one wishes to employ an
‘off-the-shelf’ siRNA delivery system. In performing this analysis,
we attempted to follow the manufacturer’s recommendations for
optimal reagent:siRNA ratio, and employed a single complexation
buffer for all reagents. It is likely that the efficiency for some
reagents may be improved with further optimization of complexation conditions, however such an effort was not spent in this study
due to extensive numbers of variables that can be optimized. Our
main goal was to identify a few obviously effective commercial
reagents and to compare our polymeric carriers to these reagents
in silencing studies (below).

3.6 Comparison of siRNA Delivery with Commercial
Reagents
The best performing polymeric carrier, PEI2-LA, was next
compared to several commercial reagents for siRNA delivery to
AML cells. The commercial reagents were chosen based on their
previous use for siRNA delivery to leukemic cells (see Introduction). All of the commercial reagents were cationic liposomes, since
no polymeric carrier was utilized in leukemic cells previously. The
siRNA delivery was investigated at the polymer:siRNA ratios of
8:1 and 4:1, but the results from the 8:1 ratio is shown only since
the results from the 4:1 ratio also gave equivalent outcomes. The
results were summarized as either the percentage of siRNApositive cells (Figure 11A), or the extent of siRNA delivery per
cell (Figure 11B). The siRNA delivery by the chosen reagents
varied significantly, depending on the cell line. Fugene HD,
PEI25, Metafectamine and PEI2-LA were the carriers with the
highest delivery percentages (.80%; Figure 11A), whereas
LipofectamineTM 2000, RNAiMAX, DOTAP and HiPerFect
displayed variable results depending on the cell line. Based on the
mean fluorescence levels, Metafectamine, LipofectamineTM 2000
and PEI2-LA were the top three carriers (Figure 11B), but RNAimate and DOTAP did not demonstrate significant delivery at all.
The polymeric PEI2-LA was among the top three carriers when
ranked in both the mean siRNA fluorescence (Figure 11C, top)
PLOS ONE | www.plosone.org
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Figure 10. Effect of serum on siRNA/polymer complex delivery to THP-1, KG-1 and HL-60 cells. (A) THP-1 (B) KG-1, and (C) HL-60 cells.
siRNA concentration was 25 nM (35 mg/mL) and polymer:siRNA weight ratio was 8:1. The results are summarized as percentage of siRNA positive cells
(top panel) and mean fluorescence per cell (middle panel).
doi:10.1371/journal.pone.0044197.g010

more effective in GFP silencing, with 20–26% GFP silencing
achieved after 3 days of siRNA delivery. A dose-response curve
was then explored with the lipid-substituted polymers at 4:1 and
8:1 polymer:siRNA ratios (Figure 12C). When silencing was
based on mean GFP fluorescence, a gradual increase in GFP
silencing was evident for some groups between 20 and 100 nM
siRNA concentration (e.g., for CA and LA substituted PEI2 at 8:1
ratio), but not beyond the 100 nM siRNA concentration. Such
clear dose-response curves were not evident for silencing based on
percentage of GFP-positive cells (Figure 12C).
The silencing efficiency of the polymeric carriers (PEI2-LA and
PEI2-CA) and three effective commercial reagents (LipofectamineTM 2000, Metafectamine and Fugene HD) were compared next
(Figure 12D). GFP silencing was assessed over a period of 9 days
after a single siRNA delivery. Although PEI25 was also included in
this experiment, only a small fraction of cells (,5%) survived on
the long run so that it was omitted from the analysis. The siRNA
delivery resulted in most significant GFP silencing on day 3 for all
delivery systems, and silencing was typically lost by 9 days
(Figure 12D). LipofectamineTM 2000 gave the highest silencing
(,62% on day 3 based on mean GFP fluorescence), followed by
the two lipid-substituted PEIs and Metafectamine (,40% on day

3.7 Silencing of Reporter (GFP) Gene Expression
To explore the silencing efficiency of the developed polymers,
GFP-expressing THP-1 cells were used as a model system. The
reduction in GFP expression was expressed as either a percent
decrease in mean GFP fluorescence or percent decrease in GFPpositive cells (Figure 12). Note that the extent of GFP expression
in the modified THP-1 cells was typically 3 logs higher than the
background in unmodified cells (unmodified cells appeared in first
quadrant of the histograms; not shown). The GFP silencing was
evident by a leftward shift in the histograms (see Figure 12A), but
at no point complete GFP silencing was obtained in this study.
The control siRNA employed led to minor (insignificant) changes
in GFP fluorescence of the cells at times, so that the changes in
GFP fluorescence was normalized against CsiRNA treated cells (as
described in Methods). The initial study focussed on comparing
the PEI25 to two of the lipid substituted polymers (PEI2-CA and
PEI2-LA) with higher siRNA delivery efficiency to THP-1 cells
(from Figure 9). At the three polymer:siRNA ratios tested (2:1,
4:1 and 8:1), both lipid substituted polymers gave a higher
silencing activity than PEI25, whose silencing efficacy was not
significant (Figure 12B). Unlike the delivery results, where LA
substitution gave the most delivery, CA substitution was generally
PLOS ONE | www.plosone.org
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Figure 11. siRNA delivery to THP-1, KG-1 and HL-60 cells by commercial reagents. siRNA delivery after 24 hours was expressed as the
siRNA-positive cell population (A) or mean fluorescence of cell population (B). (C) Relative ranking of various reagents based on mean fluorescence
(top panel) or percentage of siRNA-positive cell population (bottom panel). Results from all three cell types were pooled for the ranking.
doi:10.1371/journal.pone.0044197.g011

16], since these studies were more concerned with elucidating the
biological roles of specific targets, rather than safety and efficacy of
the delivery system.
To confirm whether the silencing observed with GFP-positive
cells also reflected silencing at the mRNA level, GFP mRNA levels
in treated THP-1 cells was quantitated by PCR. A significant
decrease in mRNA levels was observed with PEI2-CA delivered
siRNA on day 1 and 2, after which insignificant change was seen
on day 3 (Figure 13A). The cells exposed to PEI25 and PEI2-LA
delivered siRNA did not yield as significant silencing at the mRNA
level (Figure 13A). As before, silencing was additionally
confirmed based on changes in GFP-positive cells and mean
GFP levels, especially with PEI2-CA (Figure 13Bi and 13Bii,
respectively). It appeared that flow-cytometric assessment of GFP
silencing was more readily detectable as compared to PCR-based
assessment, given large variations observed with the latter assay.
However, both PCR and flow cytometric based evaluation of
silencing suggested the CA-substituted polymers to be more
effective in functional siRNA delivery.

3). Similar conclusions were reached when GFP silencing was
analysed based on the decrease in GFP-positive cells.
However, a major difference was seen in cell numbers analysed
by the flow cytometry; (i) while LA substituted PEI2 did not give
any long term adverse effects on cells (i.e., cell numbers were
equivalent to no-treatment controls), CA substituted PEI2 gave
lower cell numbers especially after day 3; (ii) LipofectamineTM
2000 in particular resulted in gradual loss of cell survival to levels
,5% of the un-treated cells, indicating long terms adverse effects
on the cells, and (iii) Metafectamine and Fugene HD gave
intermediate effects on the cells, where the cell numbers typically
remained at the ,50% level to that of no-treatment controls. The
long-term adverse effects on cells are obviously not desirable for
systemic administration of delivery systems due to undesirable
effects on healthy cells. The difference in the toxicity of CA and
LA substituted PEI2 was noteworthy in the silencing studies and
was not apparent in the initial studies (see Figure 4). The silencing
studies employed cell concentrations from flow cytometry as a
measure of toxicity, whereas the initial toxicity studies investigated
cell viability by the MTT. While the results from CA substitutions
agreed with both methods, results with LA substitution did not
agree between the two methods. This issue requires further
investigation but it appears that LA substitution seems to be more
desirable for longer exposure to the cells. Despite effective
silencing, the toxicity of LipofectamineTM 2000 was considered
prohibitive for in vitro use (since aberrant cellular physiology could
complicate the investigated silencing phenomena) as well as in vivo
use (too toxic for non-target cells and tissues). Such high toxicities
were not evident in previous studies employing this reagent [11–
PLOS ONE | www.plosone.org

3.8. Down-regulation of Endogenous CXCR4 Levels
The G protein-coupled chemokine receptor CXCR4 is an
endogenous protein that has implications in abnormal proliferation of leukemic cells, migration and anchorage to the bone
marrow [56] and with differential expression as a response to drug
treatments including valproic acid (VPA) depending on maturation level of the cells [57]. Since THP-1 cells display high level of
CXCR4 expression (.80% positive), we explored the feasibility of
down-regulating the level of this endogenous protein since
15
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Figure 12. Silencing in GFP-expressing THP-1 cells. (A) The cell counts as measured by flow cytometry (expressed as a percentage of nontreated cells). (B) Silencing was assessed after 3 days of siRNA treatment (50 nM) and expressed as decrease in mean GFP fluorescence or decrease in
GFP-positive cells. The polymer:siRNA ratios were 2:1, 4:1 and 8:1. (C) Dose-response curves for GFP silencing between 25 and 200 nM siRNA
treatment. The CA and LA substituted polymers were used at the polymer:siRNA ratios of 4:1 and 8:1, and silencing was assessed after 3 days of
treatment. (D) Silencing by CA- and LA-substituted polymers and three commercial reagents (LipofectamineTM 2000, Metafectamine and Fugene HD).
The extent of silencing was summarized over a course of 9 days and expressed as decrease in mean GFP fluorescence (top panel) or decrease in GFPpositive cells (middle panel). The lipid substitutions of the polymers used were 2.1 LA/PEI (PEI2-LA) and 6.9 CA/PEI (PEI2-CA).
doi:10.1371/journal.pone.0044197.g012
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Figure 14. CXCR4 Silencing in THP-1 cells. Changes in CXCR4
levels based on (A) mean CXCR4 fluorescence intensity and (B) CXCR4positive cell population. Silencing was assessed after 2 and 3 days of
CXCR4-specific siRNA or control siRNA treatment (50 nM with
polymer:siRNA ratio of 4:1). The polymers used were PEI25, PEI2-LA
(2.1 LA/PEI) and PEI2-CA (6.9 CA/PEI).
doi:10.1371/journal.pone.0044197.g014

Figure 13. GFP mRNA and protein suppression in THP-1 cells.
(A) Decrease in GFP mRNA levels, and (B) decrease in GFP protein levels
(i: based on mean GFP fluorescence and ii: based on GFP-positive cell
population). The GFP-positive THP-1 cells were treated with 50 nM GFP
siRNA (or control siRNA) delivered with PEI25, PEI2-LA (2.1 LA/PEI) and
PEI2-CA (6.9 CA/PEI; 4:1 = polymer:siRNA ratio) for 1 to 3 days, after
which the cells were harvested for PCR (A) and flow cytometry (B).
doi:10.1371/journal.pone.0044197.g013

They observed a concentration-dependent effect of siRNA in
various genes with siRNA concentrations at .25 nM [59].
Semizarov et al. also observed off-target effects of siRNA at
100 nM, but not at 20 nM [60]. Therefore, the delivery
formulations developed in this study appear to function favourably
considering this constraint. Being a reporter protein, GFP
silencing was not expected to lead to any functional changes and
silencing specific targets for desirable functional changes are under
study at the present time. CXCR4-silencing, on the other hand,
are expected to yield several functional outcomes, such as reduced
migration, abnormal proliferation and reduction in cellular
anchorage to bone marrow [57], and thereby reduced cell
survival. These effects will be the focus of further studies. We
noted that previous silencing studies with leukemic cells rarely
reported quantitative results due to the mechanistic nature of the
studies. Some studies reported quantitative silencing outcomes; (i)
.80% and .95% FADD protein silencing with LipofectamineTM
2000 (100 nM siRNA) in U937 [14] and K562 [15] cells, (ii)
,90% E2F1 protein silencing in Jurkat T-cells with HiPerFect
(siRNA concentration not specified) [19], ,70% BCR-ABL
protein silencing with LipofectamineTM 2000 (60–180 nM siRNA)
and a Tat–LK15 peptide in K562 cells [16], and (iv) ,60% Bcr-abl
mRNA with DOTAP (54 pM siRNA – an exceptionally low dose)
in CML cells [20]. Our silencing results were not as high as these
values, but it must be pointed out that our cells had exceptionally
high GFP levels and complete silencing was not considered a
realistic goal with this protein. The CXCR4 down-regulation,
however, was not also as high as the values reported by other

silencing CXCR4 may prove beneficial in leukemia treatments.
After treatment with 50 nM CXCR4-specific siRNA in THP-1
cells, a significant decrease in the mean CXCR4 level was
achieved at day 2 with PEI2-CA and by day 3 with PEI2-LA
(Figure 14A). Similar to the GFP silencing results, the most
effective polymer was PEI2-CA, however, PEI2-LA was only
slightly less efficient and PEI25 was not effective in this case. The
extent of maximal decrease in the CXCR4 levels was 20–30%, a
value similar to the extent of silencing observed with the GFP. A
decrease in CXCR4-positive cell population occurred with a
decrease of 8.9% for PEI2-LA20 and 6.8% for PEI2-CA20
(Figure 14B). Unlike the GFP, CXCR4 is highly dynamically
regulated [57,58] and it is possible that rapid regulation of
CXCR4 levels could effect silencing in the cell population.
Considering all silencing results, it appeared that the designed
polymers gave effective silencing (up to ,35% based on GFP
silencing and ,30% based on CXCR4 levels) between 25 and
50 nM siRNA concentration and the benefit of employing higher
siRNA concentrations was not immediately evident. Non-specific
effects of siRNA treatment were investigated previously [59,60].
Persengiev et al. reported an increase as well as a decrease in the
expression of various mammalian genes in response to a luciferase
siRNA treatment (where no natural target is expected to exist).
PLOS ONE | www.plosone.org
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groups. The results from LipofectamineTM 2000 mediated
silencing in this study as compared to other studies might serve
as a good indicator of the differences in cell models used for
silencing. The silencing efficiency in this study should be
considered for comparison purposes for efficacy and toxicity
among the carriers, and not in the context of therapeutic studies.
Such studies with relevant molecular targets (including CXCR4)
are currently underway in the authors’ labs.
Finally, we explored the utility of our polymers for silencing in
two additional cell types, the Hut78 cells (a T-cell lymphoma cell
line) and the K562 cells (a chronic myeloid leukemia cell line)
using the reporter GFP as the target. These cells display
constitutive GFP expression similar to the THP-1 cells extensively
used in this study. Preliminary results indicated the feasibility of
GFP silencing in the Hut78 cells, most effectively with PEI2-LA
(Figure S3A). The silencing in K562 cells was to a lesser extent
with PEI2-LA, suggesting that the performance of the developed
polymeric systems could depend on the specific cell type. Such a
differential performance was also evident with the PEI25 mediated
GFP-specific siRNA (Figure S3B), where performance of PEI25
in K562 cells was superior to the Hut78 cells.

and it will be the next stage in evaluation of the proposed delivery
systems.

Supporting Information
Figure S1 Effect of complexation time on siRNA delivery. PEI2LA20 was delivered after complexes were prepared and incubated
at room temperature from 0–120 minutes.
(PDF)
Figure S2 Effect of free fatty acids on siRNA-polymer delivery.
(A) Fatty acids were pre-treated for 24 h with LA and then
incubated with FAM siRNA/polymer complexes (1:2 and 1:8
polymer:siRNA ratios) for 24 h. (B) Various fatty acids were
delivered with siRNA-polymer (25 nM at 1:8 polymer:siRNA
ratio) treatments simultaneously to THP-1 cells for 24 h.
(PDF)
Figure S3 GFP Silencing in GFP-Positive Hut78 (A) and K562
(B) cells. GFP silencing was measured 3 days after siRNA
treatment with 25 nM (Hut78 cells) and 36 nM (K562) GFP
siRNA (or control siRNA) at indicated polymer:siRNA ratios.
Percent decrease in GFP-positive cells are indicated in the top
graphs whereas percent decrease in the mean GFP levels are
indicated in bottom graphs.
(PDF)

Conclusions
Lipid modification of the ineffective polymer PEI2 clearly
improved its ability to deliver siRNA to leukemic cells. Enhanced
siRNA delivery was obtained with the appropriate choice of lipid
for polymer substitution, whose delivery ability was dependent on
(i) lipid substitution levels and (ii) polymer:siRNA ratio used for
complex formation. Compared to the commonly used polymeric
carrier PEI25, the leading lipid-substituted polymer PEI2-LA gave
siRNA delivery that was less dependent on serum concentration in
medium. Among the three types of AML cells explored, cell-to-cell
differences in siRNA delivery was evident, suggesting that
optimization of siRNA complex formulations might be needed
to maximize the delivery for individual cell types. The PEI2-LA
compared favourably to several commercial siRNA delivery
systems, and provided an effective silencing activity without
significantly affecting the subsequent cell growth. Silencing was
demonstrated by using a reporter (GFP) gene as well as the
endogenous protein CXCR4 in THP-1 cells. Given the fully
disclosed nature of the PEI2-LA (unlike most commercial reagents)
and the versatility of polymeric delivery systems in general, the
proposed polymers provide excellent possibilities for therapeutic
delivery of siRNA in leukemia. The polymers could also serve as a
platform to further improve siRNA delivery by incorporating
functional groups such as cell targeting ligands and moieties
facilitating endosomal release. The in vivo efficacy of the
polymeric siRNA delivery systems was not explored in this study

Table S1 Lipid substituted 2 kDa PEI library (PEI2-Lipids).

(DOCX)
Table S2 Linear regression analysis of complex cytotoxicity.

(DOCX)
Table S3

Trends between complex cytotoxicity and lipid

substitutions.
(DOCX)
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